Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Uveal Melanoma 1Melanoma 1Hodgkin Disease 1

Interventions

Carboplatin 11pembrolizumab 10Gemcitabine 8Cisplatin 8Rituximab 7osimertinib 5durvalumab 5Specimen Handling 5Pemetrexed 5Nivolumab 5Dexamethasone 5belzutifan 4atezolizumab 4amivantamab 4Prednisone 4Paclitaxel 4Cyclophosphamide 4Bortezomib 4trastuzumab deruxtecan 3olaparib 3lazertinib 3entrectinib 3enfortumab vedotin 3daratumumab 3alectinib 3acalabrutinib 3X-Rays 3Vinorelbine 3Oxaliplatin 3Midazolam 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Dacarbazine × 90 days × Clear all
NCT03907488 2026-06-01

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
994 enrolled 11 charts 1 FDA
Lymphoid

Hodgkin Disease

NCT03070392 2026-03-17

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Immunocore Ltd

Phase 2 Completed
378 enrolled 15 charts 1 FDA
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡